Altimmune Inc Quick Ratio (ALT) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
ALT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
Altimmune Inc 's Cash & cash equivalent grew by 1756.95 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Altimmune Inc 's Quick Ratio to 101.51, Quick Ratio remained below Altimmune inc average.
Within Major Pharmaceutical Preparations industry 186 other companies have achieved higher Quick Ratio than Altimmune Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 17 to 808.
Recent developments in the treatment of non-alcoholic steatohepatitis (NASH) highlight the increasing potential of emerging therapies. Notably, Altimmune Inc. is poised to present compelling findings from its Phase 2b clinical trial of Pemvidutide, a novel therapeutic candidate for managing moderate to severe alcohol-related liver disease. This presentation will take place during the esteemed AASLD The Liver Meeting 2025, marked by a late-breaking oral podium presentation and a supporting late-breaking poster, both of which will illuminate the efficacy and safety outcomes observed over 24 weeks of treatment. Furthermore, this article delves into Altimmune s recent financial advancements, underscoring the company s robust fiscal health amidst its innovative pipeline.Non-alcoholic steatohepatitis (NASH) represents a significant global health concern, characterized by the accumulation of fat in the liver, leading to inflammation and potential progression to cirrhosis and hepatocellular carcinoma. The critical need for effective interventions in this domain has propelled research into new therapeutic agents. Altimmune Inc. s Pemvidutide emerges as a promising candidate, demonstrating the potential to modulate liver fat and improve metabolic health.
In a noteworthy development for investors, Bragar Eagel and Squire, P.C., a prominent shareholder rights law firm, has issued a reminder regarding ongoing class action lawsuits against Altimmune, Inc. (NASDAQ: ALT) and SelectQuote, Inc. (NYSE: SLQT). Stockholders of these companies are encouraged to act swiftly, as the deadlines for petitioning the court to become lead plaintiffs are approaching.As competitive dynamics continue to evolve in the biotech and insurance markets, Altimmune s recent financial performance raises eyebrows. In Q2 2025, the company reported a revenue stagnation year-over-year, marking a 0% change, while many of its competitors enjoyed a robust growth rate of 4.88%. This divergence has prompted scrutiny from investors and industry analysts alike, particularly as Altimmune struggled to translate income growth into profitability.
On the trailing twelve months basis ALT Cash & cash equivalent more than doubled by 455.1 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Altimmune Inc 's Quick Ratio to 65.01, above ALT average Quick Ratio. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Major Pharmaceutical Preparations industry 421 other companies have achieved higher Quick Ratio than Altimmune Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2843 to 3552.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
